Using Mycelium for a Sustainable Future feat. Kimberly Carlson
In this episode, David talks with Kimberly Carlson, CEO & CFO of Mushrooms Inc., a company that is aiming to bring forth a new era of sustainability with the use of mycelium.
Similar Posts
Big Pharma Steps Onto the Psychedelics Wagon
The world of medicine is constantly evolving as more and more research is conducted and breakthroughs are made. One area that has been garnering a lot of attention lately is the use of psychedelics in mental health treatment. And it seems that Big Pharma is taking notice.
Interview With Ronan Levy
In this episode of the Psychedelic Spotlight podcast, we catch up with Ronan Levy, Co-Founder and Executive Chairman of Field Trip Health, and discuss the significance behind the company’s recent opening of its psilocybin research and cultivation facility in Jamaica along with the company’s recent listing on the OTCQX.
Exclusive: Beckley Waves Establishes Ethics Council to Guide Psychedelic Industry Standards
Beckley Waves has formed a new Ethics Council.
Cathie Wood of Ark Invest Comments on Psychedelic Stocks like MindMed “We DON’T Invest In Binaries”
Will Ark Invest (ARKK) and Cathie Wood invest in MindMed ( MMED / MMEDF/ MMQ) or other Psychedelic Stocks? In this episode, Cathie Wood talks to Kevin O’Leary about the potential for psychedelic stocks and MindMed.
Kevin O’Leary is a BIG bull in MindMed, but what does Cathie Wood think? Will Ark invest in MindMed? Well, no. She is clear that Ark does not invest in binary outcomes, which MMED / MMEDF cleary is.
Having said this, the door may be left open for the future, as ARKK invests in Healthcare companies using artifical intellegence, exactly what MindMed’s Albert division is working on. Also, once clinical trial results come in, MindMed will no longer be a binary choice. SO anything is possible.
I hope this little impromptu episode added some life and joy to your live and that you guys found some value in this.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedNews #PsychedelicStocks
Will MAPS IPO? The FIRST American Psychedelic ETF (PSY), New LSD Studies & More
There were LOTS of general news important for the psychedelic industry as a whole and very important study results that will influence some of our favorite stocks such as MindMed (MMED / MNMD / MMQ) and Compass Pathways (CMPS)!
In today’s episode we’ll cover a new American psychedelic ETF which is hitting the market under ticker symbol PSY, some new psilocybin and LSD studies, whether MAPS will turn into a public company and some updates on the California and New York bills we have been covering for a while now.
Enjoy the episode!
Timestamps:
0:00 – Intro
0:40 – The First American Psychedelic ETF (PSY)
5:50 – MAPS Considering An IPO?
12:28 – Psilocybin Assisted-Therapy Is 4-Times More Effective Than Typical SSRIs
15:29 – New Study On How LSD Affects The Brain
21:08 – The California Senate Has Approved a Bill To Legalize the Possession Of Psychedelics Like Psilocybin And LSD
23:00 – New York Bill Proposes State-Sponsored Psychedelic Research Institute
Links:
New Psychedelic ETF (NYSE : PSY) :
https://www.defianceetfs.com/psy/
https://psychedelicspotlight.com/psy-first-u-s-psychedelic-etf/
Maps Considering An IPO?:
https://www.reddit.com/r/shroomstocks/comments/nqoy0z/maps_considering_ipo/
https://youtu.be/v2HycPpjf6Y
Study Shows Psilocybin Assisted-Therapy Is 4-Times More Effective Than Typical Antidepressants:
https://thedalesreport.com/psychedelics/study-shows-psilocybin-assisted-therapy-4-times-more-effective-than-typical-antidepressants/
New Study On How LSD Affects The Brain:
https://www.theguardian.com/science/2021/may/19/acid-test-scientists-show-how-lsd-opens-doors-of-perception
The California Senate Has Approved a Bill To Legalize the Possession Of Psychedelics Like Psilocybin And LSD:
https://www.marijuanamoment.net/california-senate-approves-bill-to-legalize-possession-of-psychedelics-like-psilocybin-and-lsd/
New York Bill Proposes State-Sponsored Psychedelic Research Institute:
https://psychedelicspotlight.com/new-york-bill-psychedelic-research-institute/
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #MAPS
Numinus’ BIG Patent, Mydecine Tackles A $13.6 BILLION Market & Some BUY Ratings! ( NUMI / MYCO)
BIG news for Mydecine (MYCO : NEO) (MYCOF: OTC) and Numinus Wellness (NUMI: NEO)
(LKYSF : OTC). But The BIGGER NEWS is that we are finally launching our website: https://thepsychedelicinvestor.com/, where we will be sharing the latest industry news for all of your favorite companies.
We hope we can facilitate our community’s path to information about the psychedelic sector. We would like to invite you to share your opinions and suggestions down in the comment section.
Last but not least, if you wish to collaborate and become a contributor for The Psychedelic Investor, you’re welcome to send us an email at thepsychedelicinvestor@gmail.com or fill in a form on our website! We welcome your opinion and you can have a shot at seeing your name in the opinion section of our website!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Links:
Numinus Wellness (TSXV: NUMI, OTC: LKYSF), Filed a Patent Application for their Proprietary Rapid Production Process of Psilocybe Mushrooms and Other Psychoactive Fungi Species:
https://thepsychedelicinvestor.com/2021/06/24/numinus-files-u-s-provisional-patent-application-for-a-proprietary-rapid-production-process-for-psilocybe-and-other-psychoactive-fungi-species/
Mydecine (NEO: MYCO, OTC: MYCOF), Will Attempt To Treat Substance Use Disorder and Nicotine Addiction With Their MYCO-004 Molecule:
https://thepsychedelicinvestor.com/2021/06/24/mydecine-selects-substance-use-disorder-and-smoking-cessation-for-novel-psychedelic-molecule-myco-004/
Mydecine’s 4 Proprietary Compounds Advancing To Clinical Trials: Myco 001, 002, 003, 004:
https://thepsychedelicinvestor.com/2021/04/07/mydecine-announces-four-lead-novel-drug-candidates-and-prepares-for-pre-ind-meetings-with-the-fda-and-health-canada-to-prepare-for-human-clinical/
Johns Hopkins psilocybin study results:
https://www.hopkinsmedicine.org/news/stories/mushrooms_quit_smoking.html
Roth Capital Initiates Coverage On Mydecine Innovations with Buy Rating, Announces Price Target of 3$:
https://www.benzinga.com/news/21/06/21664391/roth-capital-initiates-coverage-on-mydecine-innovations-with-buy-rating-announces-price-target-of-c
Enjoy the episode!
Timestamps:
0:00 – Intro
1:37- Numinus’ patent application to speed up their psilobe mushrooms’ production process
4:53 – Mydecine announces it will use their MYCO – 004 molecule to treat substance use disorder and addiction
9:15 – Roth Capital says that Mydecine is a BUY with a price target of $3
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Numinus #Mydecine #NUMIStock